Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats - PubMed (original) (raw)
Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats
A Lämmer et al. Eur J Neurosci. 2006 May.
Abstract
After acute injury of the central nervous system extracellular adenosine 5'-triphosphate (ATP) can reach high concentrations as a result of cell damage and subsequent increase in membrane permeability. Released ATP may act as a toxic agent, which causes cellular degeneration and death, mediated through P2X and P2Y receptors. Mechanisms underlying the various effects of purinoceptor modulators in models of cerebral damage are still uncertain. In the present study the effect of P2 receptor inhibition after permanent middle cerebral artery occlusion (MCAO) in spontaneously hypertensive rats was investigated. Rats received either the non-selective P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) or artificial cerebrospinal fluid (ACSF) as control by the intracerebroventricular route. First, these treatments were administered 10 min before MCAO and subsequently twice daily for 1 or 7 days after MCAO. The functional recovery of motor and cognitive deficits was tested at an elevated T-labyrinth. The PPADS-treated group showed a significant reduction of paresis-induced sideslips compared with ACSF-treated animals. Infarct volume was reduced in the PPADS group in comparison with the ACSF group. A significant decrease in intermediately and profoundly injured cells in favour of intact cells in the PPADS group was revealed by quantification of celestine blue/acid fuchsin-stained cells in the peri-infarct area. The data provide further evidence for the involvement of P2 receptors in the pathophysiology of cerebral ischaemia in vivo. The inhibition of P2 receptors at least partially reduces functional and morphological deficits after an acute cerebral ischaemic event.
Similar articles
- The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo.
Lämmer AB, Beck A, Grummich B, Förschler A, Krügel T, Kahn T, Schneider D, Illes P, Franke H, Krügel U. Lämmer AB, et al. PLoS One. 2011;6(5):e19983. doi: 10.1371/journal.pone.0019983. Epub 2011 May 17. PLoS One. 2011. PMID: 21611146 Free PMC article. - Multiple motor effects of ATP and their inhibition by P purinoceptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid in the small intestine of the guinea-pig.
Barthó L, Undi S, Benkó R, Wolf M, Lázár Z, Lénárd L Jr, Maggi CA. Barthó L, et al. Basic Clin Pharmacol Toxicol. 2006 May;98(5):488-95. doi: 10.1111/j.1742-7843.2006.pto_369.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16635108 - SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC. Legos JJ, et al. Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25. Exp Neurol. 2008. PMID: 18462720 - Involvement of P2 receptors in the growth and survival of neurons in the CNS.
Franke H, Illes P. Franke H, et al. Pharmacol Ther. 2006 Mar;109(3):297-324. doi: 10.1016/j.pharmthera.2005.06.002. Epub 2005 Aug 15. Pharmacol Ther. 2006. PMID: 16102837 Review. - Neuroprotective role of adenosine in cerebral ischaemia.
Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Rudolphi KA, et al. Trends Pharmacol Sci. 1992 Dec;13(12):439-45. doi: 10.1016/0165-6147(92)90141-r. Trends Pharmacol Sci. 1992. PMID: 1293870 Review.
Cited by
- Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction.
Weilinger NL, Maslieieva V, Bialecki J, Sridharan SS, Tang PL, Thompson RJ. Weilinger NL, et al. Acta Pharmacol Sin. 2013 Jan;34(1):39-48. doi: 10.1038/aps.2012.95. Epub 2012 Aug 6. Acta Pharmacol Sin. 2013. PMID: 22864302 Free PMC article. Review. - ATP as a multi-target danger signal in the brain.
Rodrigues RJ, Tomé AR, Cunha RA. Rodrigues RJ, et al. Front Neurosci. 2015 Apr 28;9:148. doi: 10.3389/fnins.2015.00148. eCollection 2015. Front Neurosci. 2015. PMID: 25972780 Free PMC article. Review. - Young age and low temperature, but not female gender delay ATP loss and glutamate release, and protect Purkinje cells during simulated ischemia in cerebellar slices.
Mohr C, Brady JD, Rossi DJ. Mohr C, et al. Neuropharmacology. 2010 Feb;58(2):392-403. doi: 10.1016/j.neuropharm.2009.09.013. Epub 2009 Oct 13. Neuropharmacology. 2010. PMID: 19825379 Free PMC article. - Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia.
Kuboyama K, Harada H, Tozaki-Saitoh H, Tsuda M, Ushijima K, Inoue K. Kuboyama K, et al. J Cereb Blood Flow Metab. 2011 Sep;31(9):1930-41. doi: 10.1038/jcbfm.2011.49. Epub 2011 Apr 13. J Cereb Blood Flow Metab. 2011. PMID: 21487414 Free PMC article. - Activation of basal forebrain purinergic P2 receptors promotes wakefulness in mice.
Yang C, Larin A, McKenna JT, Jacobson KA, Winston S, Strecker RE, Kalinchuk A, Basheer R, Brown RE. Yang C, et al. Sci Rep. 2018 Jul 16;8(1):10730. doi: 10.1038/s41598-018-29103-4. Sci Rep. 2018. PMID: 30013200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources